Thrombelastography (TEG) and Thrombin Generation Assay (TGA) in Severe Hemophilia Following Factor Replacement Therapy

被引：2
|
作者：
Sarker, Tania T. [1 ]
Brophy, Donald [2 ]
Chitlur, Meera B. [1 ]
机构：
[1] Wayne State Univ, Childrens Hosp Michigan, Div Hematol Oncol, Carman & Ann Adams Dept Pediat, Detroit, MI USA
[2] Virginia Commonwealth Univ, Richmond, VA USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.4666.4666
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Factor VIIa-dependant thrombin generation in hemophilia A.
    Butenas, S
    Brummel, KE
    Branda, RF
    Mann, KG
    BLOOD, 2000, 96 (11) : 533A - 533A
  • [42] Ex Vivo Evaluation of the Effect of Plasma-Derived Factor VIII/Von Willebrand Factor in Patients with Severe Hemophilia_A on Prophylaxis with Emicizumab By Thrombin Generation Assay
    Bravo, Maria-Isabel
    Raventos, Aida
    Perez, Alba
    Arias-Salgado, Elena G.
    Alvarez Roman, Maria Teresa
    Butta, Nora V.
    Jimenez-Yuste, Victor
    Costa, Montserrat
    Willis, Todd
    BLOOD, 2021, 138
  • [43] Thrombin generation assay (TGA) is not able to predict hemostatic efficacy of by-passing agents in patients with hemophilia and inhibitors: results from in vivo studies
    Mancuso, M. E.
    Santagostino, E.
    Chantarangkul, V
    Clerici, M.
    Fasulo, M. R.
    Tripodi, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 471 - 471
  • [44] Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors
    Ay, Y.
    Balkan, C.
    Karapinar, D. Y.
    Akin, M.
    Bilenoglu, B.
    Kavakli, K.
    HAEMOPHILIA, 2012, 18 (06) : 911 - 916
  • [45] Laboratory control of replacement therapy in severe hemophilia A patients
    Balandina, A.
    Zapariy, A.
    Polokhov, D. M.
    Yakovleva, V
    Kargaltsev, A.
    Konyashina, N., I
    Polyanskaya, T. U.
    Kopylov, K. G.
    Ataullakhanov, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 926 - 926
  • [46] Utility of converted factor VIII activity by thrombin generation assay for evaluation of clotting function among hemophilia A carriers
    Nogami, Keiji
    Kawamura, Takeshi
    Shima, Midori
    Yada, Koji
    HAEMOPHILIA, 2018, 24 : 28 - 29
  • [47] Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity
    Nummi, V.
    Jouppila, A.
    Lassila, R.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (04) : 359 - 368
  • [48] Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
    Verhagen, Marieke J. A.
    Valke, Lars L. F. G.
    Schols, Saskia E. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (04) : 794 - 805
  • [49] Does heterogeneity in measured calibrated thrombin generation assay or FVIII activity (<1%) explain clinical heterogeneity in severe hemophilia A?
    Sinclair, G. D.
    Blanchette, V
    Card, R. T.
    Chan, A. K. C.
    Israels, S.
    Lillicrap, D.
    Rivard, G.
    Robinson, S.
    Vickars, L.
    Williams, Z.
    Wu, J. K. M.
    Poon, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 189 - 189
  • [50] Replacement therapy with virus-inactivated clotting factor concentrates in patients with severe hemophilia in Heidelberg
    Zimmermann, R
    Uhle, C
    Huth-Kühne, A
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 : 75 - 78
12345